User: Guest  Login
Title:

Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms.

Document type:
Journal Article; Research Support, Non-U.S. Gov't
Author(s):
Jayavelu, Ashok Kumar; Schnöder, Tina M; Perner, Florian; Herzog, Carolin; Meiler, Arno; Krishnamoorthy, Gurumoorthy; Huber, Nicolas; Mohr, Juliane; Edelmann-Stephan, Bärbel; Austin, Rebecca; Brandt, Sabine; Palandri, Francesca; Schröder, Nicolas; Isermann, Berend; Edlich, Frank; Sinha, Amit U; Ungelenk, Martin; Hübner, Christian A; Zeiser, Robert; Rahmig, Susann; Waskow, Claudia; Coldham, Iain; Ernst, Thomas; Hochhaus, Andreas; Jilg, Stefanie; Jost, Philipp J; Mullally, Ann; Bullinger, Lars; Me...     »
Abstract:
Janus kinases (JAKs) mediate responses to cytokines, hormones and growth factors in haematopoietic cells1,2. The JAK gene JAK2 is frequently mutated in the ageing haematopoietic system3,4 and in haematopoietic cancers5. JAK2 mutations constitutively activate downstream signalling and are drivers of myeloproliferative neoplasm (MPN). In clinical use, JAK inhibitors have mixed effects on the overall disease burden of JAK2-mutated clones6,7, prompting us to investigate the mechanism underlying dise...     »
Journal title abbreviation:
Nature
Year:
2020
Journal volume:
588
Journal issue:
7836
Pages contribution:
157-163
Fulltext / DOI:
doi:10.1038/s41586-020-2968-3
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/33239784
Print-ISSN:
0028-0836
TUM Institution:
III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie)
 BibTeX